Regeneron Pharmaceuticals, Inc. (REGN) — Yes — too late. Don't buy it here.
Our model puts the odds of REGN being higher in three months at 29% — worse than a coin flip — and its three-month estimate is $659.21, 2.6% below today's $676.69. Buying now means paying more than we think it will be worth, so don't start a position at this price — a missed trade costs you nothing, this one can.
Where we'd be wrong: We're wrong if REGN closes above $705.85 within three months — the top of our 90% forecast band. Above that our model under-called the move: our call failed, and you should stop waiting on it.
The prices behind this verdict
Price today: $676.69 — What one share costs right now — the price you would actually pay if you bought today.
Odds it's higher in 3 months: 29% — How often our model expects this stock to be above today's price in three months. Below 50% means it leans down. Read it as a lean, not a certainty — 47% and 53% are both close to a coin flip.
Our 3-month estimate: $659.21 — Where our model thinks the price sits in three months — the middle of our forecast, not a promise. Below today's price means buying now is paying more than we think it will be worth.
We're wrong above: $705.85 — The top of our 90% forecast band. If the stock closes above it inside three months, our forecast was wrong — we under-called this move and you should stop waiting on us.
Why — the risk checks behind the call
The overall market is in a friendly mood: fired — the broad market is in a hostile regime, and we suspend new buy signals until it clears
Several independent signals agree: skipped — not evaluated — signal already suppressed upstream
The strategy is not on a losing streak: skipped — not evaluated — signal already suppressed upstream
This is not a near-copy of what we already hold: skipped — not evaluated — signal already suppressed upstream
There is still room for another position: skipped — not evaluated — signal already suppressed upstream
The stock is not expected to fall over the next month: skipped — not evaluated — signal already suppressed upstream
No earnings report is uncomfortably close: skipped — not evaluated — signal already suppressed upstream
Market fear is low enough to enter safely: skipped — not evaluated — signal already suppressed upstream
The market as a whole is trending upward: skipped — not evaluated — signal already suppressed upstream
The reward is big enough for the risk, at a sane position size: skipped — not evaluated — signal already suppressed upstream
We are confident enough to publish this at all: skipped — not evaluated — signal already suppressed upstream